RRC ID |
42754
|
著者 |
Jiang P, Watanabe H, Okada G, Ohtsubo K, Mouri H, Tsuchiyama T, Yao F, Sawabu N.
|
タイトル |
Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma.
|
ジャーナル |
Cancer Sci
|
Abstract |
The tissue factor pathway inhibitor 2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor. Recently, the aberrant methylation of TFPI-2 was detected frequently in pancreatic carcinoma (PCa) tissues but not in normal pancreatic tissues. We analyzed the aberrant methylation of TFPI-2 in the pure pancreatic juice (PPJ) aspirated endoscopically from patients with various pancreatic diseases. Using the highly sensitive methylation-specific polymerase chain reaction (MSP) and quantitative MSP (Q-MSP) assay, we investigated the aberrant methylation of TFPI-2 in nine human PCa cell lines and in the PPJ from patients with PCa, intraductal papillary mucinous neoplasms (IPMN) and chronic pancreatitis (CP). The incidence of aberrant TFPI-2 methylation was seven (77.8%) of nine PCa cell lines by Q-MSP. In cell lines, the expression of TFPI-2 mRNA by quantitative reverse transcription-polymerase chain reaction showed an inverse correlation to the aberrant methylation of TFPI-2. The incidence of aberrant TFPI-2 methylation in the PPJ was 21 (58.3%) of 36 PCa patients, three (17.6%) of 17 IPMN and one (4.8%) of 21 CP by MSP assay. Using a suitable cut-off value of 2.5 according to the receiver operating characteristic curve, the incidence of aberrant TFPI-2 methylation in the PPJ by real-time MSP was 18 (62.1%) of 29 PCa patients, one (5.1%) of 17 IPMN and three (14.3%) of 21 CP, respectively. The incidence of quantitative TFPI-2 hypermethylation in the PPJ with PCa was significantly higher than that with IPMN (P < 0.001) or CP (P < 0.001). Moreover, the aberrant methylation rate of TFPI-2 in the PPJ was 100%, as observed (6/6) in the PCa patients with liver metastasis, and 86.7% (26/30) in stages IVa + IVb of PCa by Q-MSP assay. These results suggest that promoter methylation of TFPI-2 in the PPJ may be a useful marker in the diagnosis and progression of PCa using an endoscopically feasible approach.
|
巻・号 |
97(11)
|
ページ |
1267-73
|
公開日 |
2006-11-1
|
DOI |
10.1111/j.1349-7006.2006.00308.x
|
PII |
CAS308
|
PMID |
16965396
|
MeSH |
Adenocarcinoma, Mucinous / diagnosis
Adenocarcinoma, Mucinous / genetics
Aged
Antimetabolites, Antineoplastic / pharmacology
Azacitidine / pharmacology
Carcinoma, Pancreatic Ductal / diagnosis
Carcinoma, Pancreatic Ductal / genetics
Carcinoma, Papillary / diagnosis
Carcinoma, Papillary / genetics
Cell Line, Tumor
DNA Methylation*
DNA, Neoplasm / genetics
DNA, Neoplasm / metabolism
Female
Gene Expression Regulation, Neoplastic
Glycoproteins / genetics*
Humans
Male
Middle Aged
Pancreatic Juice / metabolism*
Pancreatic Neoplasms / diagnosis*
Pancreatic Neoplasms / genetics*
Pancreatitis, Chronic / genetics
Pancreatitis, Chronic / pathology
Polymerase Chain Reaction
Promoter Regions, Genetic
RNA, Neoplasm / genetics
RNA, Neoplasm / metabolism
Reverse Transcriptase Polymerase Chain Reaction
|
IF |
4.966
|
引用数 |
22
|
WOS 分野
|
ONCOLOGY
|
リソース情報 |
ヒト・動物細胞 |
MIA Paca2(RCB2094) |